Company Active LTD

Company profile

Beyond Blood Diagnostics Ltd

Home - Beyond Blood | At Home Blood Count Monitoring

Beyond Blood Diagnostics Ltd is a UK company with status active founded in 2022.

CRN
13826151
Founded
2022
Age
4

Overview

Legal name
BEYOND BLOOD DIAGNOSTICS LTD
Region
Unknown
Registered address
UNIT 120
242 ACKLAM ROAD
LONDON
ENGLAND
W10 5JJ
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

Beyond Blood Diagnostics Ltd
No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

6 events
02 Apr
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Oct
2026

Accounts due

Accounts Due

Next accounts due date

19 Mar
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jan
2025

Accounts filed

Accounts

Last accounts made up date

09 Aug
2024

Accounts With Accounts Type Micro Entity

Accounts Awaiting analysis

AA | Transaction MzQzMTc0NTIxNWFkaXF6a2N4

Published 09 Aug 2024 16:07

04 Jan
2022

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2022
Funded years
2022, 2023
Age at first award
0 years

Projects

2023 Collaborative R&D Lead participant

A novel diagnostic tool leveraging AI for protein design and microfluidics for better cell therapy management

1 Dec 2023 to 31 Dec 2025

Awarded
£323,889
Total cost £539,815

A vital part of cancer cell therapy is to ensure that cells fighting the cancer (called T-cells) don't lose their ability to fight cancer cells or infections, a dysfunctional state called T-cell exhaustion. T-cell exhaustion plays a crucial role in the failure of cancer cell therapy. However, current hospitals and pharma companies lack the means to measur...

2023 Collaborative R&D

PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool

1 Nov 2023 to 31 Mar 2026

Awarded
£184,380
Total cost £263,400

Patients with advanced cancers are often treated with chemotherapy which can reduce the effectiveness of the body's own immune system and leave patients exposed to infection. The manufacturers of chemotherapy drugs generally suggest using the same amount of drug for everybody who needs it, however, we know that because everyone is different, people end up...

2023 Collaborative R&D Lead participant

Quantum technology enabled blood diagnostics for safer and more patient centric cancer care & treatment management

1 Oct 2023 to 30 Sep 2025

Awarded
£435,165
Total cost £621,664

A vital part of cancer therapy is to ensure the exact type and progression of the cancer is known for every patient. Unfortunately, this is very challenging, as cancer is a highly complex disease that changes over time. The way the tumours grow is incredibly complex. Doctors are frequently unsure if a patient will get better when given a particular drug. ...

2022 Collaborative R&D Lead participant

R&D safe & convenient home based blood cell counting system for the improved response to chronic disease management

1 Aug 2022 to 30 Nov 2023

Awarded
£302,258
Total cost £431,797

This application is focused on providing chronically ill patients with a highly convenient and easy way to self monitor the number of white blood cells in their blood during their illness. White blood cells are a vital part of our immune systems and serve as the primary defence against infections in the body by destroying bacteria, bacterial fragments and...

Product types

Collaborative R&D